The safety of bone-marrow derived mesenchymal stem cells in patients with type 2 diabetes mellitus

The potential role of mesenchymal stem cells (MSCs) in the management of Type 2 diabetes mellitus (T2DM) has been shown with varying degrees of success in animal models and in clinical trials. Evidence shows that it affects insulin resistance and secretory dysfunction of B-cells. It has also shown potential effects on immune system dysregulation and inflammatory mediators, both of which are involved in the basic pathogenesis of T2DM. The objective of our study was to determine the effect of MSC infusion on patients with advanced T2DM.